2024年1月6日~2024年1月12日の間に収集した論文情報を追加しました。
1. Ocular toxicity associated with anti-HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database.
抗HER2薬の眼毒性リスクをFAERSで調査
対象DB:FAERS
2. Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database.
セクキニュマブ使用に関連する有害事象をFAERSから調査
対象DB:FAERS
3. A Real-World Data Derived Pharmacovigilance Assessment on Drug-Induced Nephropathy: Implication on Gaps in Patient Care.
KAERSにおける薬剤誘発性腎毒性の有病率と重篤性を調査
対象DB:FAERS,KAERS
4. Medication Associations with Severe Cutaneous Adverse Reactions: A Case/Non-Case Analysis Using the FDA Adverse Event Reporting System.
FAERSを用いて、SJS、TEN、DRESS、AGEPといった重篤な皮膚副作用を引き起こす可能性のある薬物を調査
対象DB:FAERS
5. Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.
FAERSを用いてQT延長およびTdPに関連する報告をレビュー
対象DB:FAERS
6. A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database.
FAERSを用いてメポリズマブの副作用を評価
対象DB:FAERS
7. Disproportionality analysis of stomatitis associated with anticancer drugs using Japanese Adverse Drug Event Reporting Database.
JADERを用いて、さまざまながん患者において抗がん剤と口内炎の関連を検討
対象DB:JADER
8. Leveraging COVID-19 Vaccine Safety Monitoring in Ethiopia and Pakistan to Enhance System-Wide Safety Surveillance.
エチオピアとパキスタンでは、COVID-19ワクチンの副反応モニタリングのため、薬剤監視システムの報告数および因果関係の評価が向上
対象DB:VigiBase
9. Autoimmune disorders reported following COVID-19 vaccination: A disproportionality analysis using the WHO database.
COVID-19ワクチン接種後の自己免疫障害に関連した16の有害事象の潜在的な安全性シグナルをVigiBaseで評価
対象DB:VigiBase
10. Safety of COVID-19 Vaccination During Pregnancy and Lactation: A VigiBase Analysis.
COVID-19ワクチン接種と妊娠・授乳の関連の検討
対象DB:VigiBase
11. Evaluation of hospital pharmacists' activities using additional reimbursement for infection prevention as an indicator in small and medium-sized hospitals.
日本の病院で追加報酬を受けるための感染症予防活動(ARIP)が導入され、100~299床の病院の薬剤師の活動を調査
対象DB:DPC
12. Treatment patterns and drug survival for generalized pustular psoriasis: A patient journey study using a Japanese claims database.
日本での全身性膿疱性乾癬の実態調査
対象DB:MDV
13. Persons diagnosed with COVID-19 in England in the Clinical Practice Research Datalink (CPRD): a cohort description.
CPRD Aurumを用い、COVID-19の確定診断、ワクチン接種状況、高リスクの3つの定義を作成
対象DB:CPRD
14. Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort study.
FIB-4指数と肝疾患、心血管イベント、全死因死亡の関連を検討
対象DB:CPRD
15. Clostridioides difficile infections, recurrences, and clinical outcomes in real-world settings from 2015-2019: The RECUR England study.
英国におけるクロストリジオイデス・ディフィシル感染、再発の疫学的および臨床的負担を評価
対象DB:CPRD
16. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
ランダム化、二重盲検、プラセボ対照の第3相試験で、リナクロチドの小児機能性便秘への効果と安全性が評価
対象DB:CVAR